![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
High Dose Pegasys/rbv can improve SVR: Impact of higher doses of peginterferon alfa-2a and ribavirin on RVR, cEVR and SVR in HCV G1 patients with viral loads ≥400 000 IU/mL weighing ≥85 kg
|
|
|
Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria
K.R. Reddy,1 M.L. Shiffman,2 M. Rodriguez-Torres,3 D. Abdurakhmanov,4 I. Bakulin,5 G.F. Silva,6 H. Cheinquer,7 M. Rabbia,8 M. McKenna,9 A. Tietz,10 S.A. Harrison,11 on behalf of the PROGRESS Study Investigators
1Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 2Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, USA; 3Fundacion de Investigacion de Diego, Santurce, PR, USA; 4Moscow Medical Academy, Moscow, Russia; 5State Postgraduate Medical Institute,
Ministry of Defence of the Russian Federation, Moscow, Russia; 6Botucatu School of Medicine, Botucatu, Brazil; 7Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil; 8Roche, Nutley, NJ, USA; 9Roche, Welwyn, UK; 10Roche, Basel, Switzerland; 11Brooke Army Medical Center, Houston, TX, USA
This research was funded by Roche, Basel, Switzerland
![](../images/042310/042310-4/image002.gif)
![](../images/042310/042310-4/image004.gif)
![](../images/042310/042310-4/image006.gif)
![](../images/042310/042310-4/image008.gif)
Figure 1. PROGRESS study design
![](../images/042310/042310-4/image010.gif)
![](../images/042310/042310-4/image012.gif)
![](../images/042310/042310-4/image014.gif)
![](../images/042310/042310-4/image016.gif)
Figure 2. Virological response rates for the four treatment arms
![](../images/042310/042310-4/image018.gif)
![](../images/042310/042310-4/image020.gif)
Figure 3. SVR rates in patients receiving ≥80% of the cumulative dose of peginterferon alfa-2a and ribavirin
![](../images/042310/042310-4/image022.gif)
Figure 4. Predictors of SVR
![](../images/042310/042310-4/image024.gif)
![](../images/042310/042310-4/image026.gif)
Figure 5. SVR rates according to on-treatment responses
![](../images/042310/042310-4/image028.gif)
Figure 6. SVR rates according to (A) baseline NAS, (B) baseline steatosis score, (C) baseline homeostasis model of assessment-insulin resistance (HOMA-IR) and (D) baseline body weight
![](../images/042310/042310-4/image030.gif)
![](../images/042310/042310-4/image032.gif)
![](../images/042310/042310-4/image034.gif)
![](../images/042310/042310-4/image036.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|